If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSeeing Machines Regulatory News (SEE)

Share Price Information for Seeing Machines (SEE)

Share Price is delayed by 15 minutes
Get Live Data
4.685    0.065 (1.41%)
Bid:
4.70
Ask:
4.725
Spread: 0.025 (0.532%)
Market Cap: £224.86m
SEE Live PriceLast checked at - London Stock Exchange

Intraday Seeing Machines Share Chart

Seeing Machines inks additional Occula NPU licence

20 Apr 2022 07:00

RNS Number : 5954I
Seeing Machines Limited
20 April 2022
 

 

Seeing Machines Limited

 

20 April 2022

 

Seeing Machines inks additional Occula® NPU licence

 

Seeing Machines Limited (AIM: SEE, "Seeing Machines" or the "Company"), the advanced computer vision technology company that designs AI-powered operator monitoring systems to improve transport safety, has signed an IP licence agreement ("Agreement") for its Occula® Neural Processing Unit (NPU) with an additional US based semiconductor company.

 

Representing the second licence of its Occula® NPU into the automotive semiconductor ecosystem, this Agreement will target development of a single semiconductor product with the option to expand into a larger family of devices. The licence facilitates another fully hardware accelerated and optimised silicon platform, via the Occula® NPU, exclusively enabling Seeing Machines' leading e-DME (embedded Driver Monitoring Engine / software) in a cost, performance, and power optimised fashion for automotive driver, occupant, and interior monitoring applications.

 

Licensing the Occula® NPU is the third pillar of the Company's "three-pillar embedded product strategy", which also includes it's FOVIO Chip solution and e-DME Software offering, and represents Seeing Machines' strategic approach to meeting the fast-growing needs of the global automotive interior monitoring market.

 

Occula® is a unique, application specific NPU that has been specifically designed to enable highly efficient human detection and tracking. It is also capable of running optimised networks (such as MobileNet and Resnet) to allow for efficient execution of state-of-the-art multi-object single-shot detection, achieving maximum silicon utilisation and minimum cost of processing.

 

Paul McGlone, CEO of Seeing Machines commented: "This additional IP license is an important milestone for Seeing Machines. It represents more validation that our three-pillar, systems focused, strategy is fitting and supportive of the automotive industry as it evolves rapidly to meet regulatory and customer demand with additional safety and functional outcomes, while minimising cost, package space, and power.

 

"Occula is an important performance enabler for devices that employ it, and we expect it to continue to drive market share and revenue expansion for our FOVIO e-DME product offering. Seeing Machines will continue to innovate our algorithm pipeline in line with our Occula NPU to ensure we continue to offer the most sophisticated and efficient processing options to our customers."

 

Enquiries:

 

Seeing Machines Limited

+61 2 6103 4700

Paul McGlone - CEO

Sophie Nicoll - Corporate Communications

Stifel Nicolaus Europe Limited (Nominated Adviser and Broker)

+44 20 7710 7600

Alex Price

Nick Adams

Ross Poulley

Lionsgate Communications (Media Enquiries)

Jonathan Charles

+44 7791 892509

 

About Seeing Machines (AIM: SEE), a global company founded in 2000 and headquartered in Australia, is an industry leader in vision-based monitoring technology that enable machines to see, understand and assist people. Seeing Machines' technology portfolio of AI algorithms, embedded processing and optics, power products that need to deliver reliable real-time understanding of vehicle operators. The technology spans the critical measurement of where a driver is looking, through to classification of their cognitive state as it applies to accident risk. Reliable "driver state" measurement is the end-goal of Driver Monitoring Systems (DMS) technology. Seeing Machines develops DMS technology to drive safety for Automotive, Commercial Fleet, Off-road and Aviation. The company has offices in Australia, USA, Europe and Asia, and supplies technology solutions and services to industry leaders in each market vertical.

 

www.seeingmachines.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCEAELNFENAEFA
Date   Source Headline
18th Sep 20069:45 amRNSGlaucoma Grant Signed
30th Aug 200611:46 amRNSClinical Study Results
14th Aug 200610:57 amRNSGrant Approval
6th Jul 20069:12 amRNSDirector/PDMR Shareholding
29th Jun 20069:37 amRNSEmployee Share Option Scheme
27th Jun 200610:11 amRNSGrant of US Patent
5th Jun 200610:14 amRNSHolding(s) in Company
10th May 20069:27 amRNSHolding(s) in Company
13th Apr 20063:25 pmRNSDirector/PDMR Shareholding
13th Apr 200612:47 pmRNSNew faceLAB Camera Product
10th Apr 20069:19 amRNSMajor Industry Awards Win
15th Mar 20067:01 amRNSInterim Results
3rd Mar 20069:42 amRNSAGM Statement-Amendment
28th Feb 20069:15 amRNSAGM Statement
8th Feb 20069:25 amRNSHolding(s) in Company
31st Jan 20069:30 amRNSHolding(s) in Company
25th Jan 20069:24 amRNSHolding(s) in Company
10th Jan 20069:18 amRNS1st Glaucoma Trial Completion
20th Dec 20053:46 pmRNSIssue of Equity
6th Dec 20059:41 amRNSHolding(s) in Company
1st Dec 20058:53 amRNSAdmission to AIM-Replacement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.